Observational studyDigestive diseases and sciences2024

Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study.

Mariabeatrice Principi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.